Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9230506 | 0.87 | RAPGEF4 (0.32) | RAPGEF4TSHRESR1 | |
| SCHEMBL15935764 | 0.85 | RAPGEF4 (0.34) | HDAC1HDAC6GPR3RAPGEF4TSHR | |
| SCHEMBL9069714 | 0.80 | RAPGEF4 (0.34) | RAPGEF4ESR1 | |
| SCHEMBL24144588 | 0.79 | KDM1A (0.43) | RAPGEF4 | |
| SCHEMBL21872501 | 0.79 | CYP3A4 (0.37) | HDAC1TSHR | |
| SCHEMBL19199591 | 0.79 | RAPGEF4 (0.33) | RAPGEF4 | |
| SCHEMBL18807949 | 0.79 | RAPGEF4 (0.37) | RAPGEF4 | |
| SCHEMBL19198529 | 0.78 | CYP3A4 (0.36) | RAPGEF4TSHRESR1 | |
| SCHEMBL31513825 | 0.78 | RAPGEF4 (0.33) | HDAC1HDAC6RAPGEF4 | |
| SCHEMBL20160730 | 0.78 | ESR1 (0.35) | RAPGEF4ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217970-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217970-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | ERBB2, JAK2, ERBB4 | HDAC1 665/4885HDAC6 1019/4885GPR3 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.